

# SESSION 4: NEXT STEPS

Moderator: Sheng Lin-Gibson, NIST

- Meeting summary
- Key concepts / outline for whitepaper
- Other businesses

[https://www.surveymonkey.com/r/CCW\\_idea\\_box](https://www.surveymonkey.com/r/CCW_idea_box)

<b>Workshop Goals</b>	<b>Actions and potential solutions</b>
Raise awareness of the importance and challenges associated with cell counting measurements	<ul style="list-style-type: none"> <li>• Whitepaper</li> <li>• Additional NIST-FDA workshops</li> </ul>
Develop and document best practices for cell counting	<ul style="list-style-type: none"> <li>• Whitepaper</li> <li>• Develop methods of general use through appropriate forums</li> </ul>
Discuss options to address measurement challenges through collaborative studies (NIIMBL)	<ul style="list-style-type: none"> <li>• Send R&amp;D topics to NIIMBL/TAC for funding to advance biomanufacturing</li> </ul>
Workshop outcomes to support the development of international standards and more specific measurement challenges	<ul style="list-style-type: none"> <li>• Cell counting serves as a use case for upcoming ISO standard effort for cell characterization</li> </ul>

# Recap

- Overarching theme: Counting is important
- Many use cases, important considerations, lessons learned, opportunities/new technologies
- FDA does not require prescriptive methods:
  - fit for purpose
  - system suitability
- Example of measurement assurance strategies for cell counting

# Terminology

- What is required during qualification, validation, and verification

# Fit for purpose

- I would like to count AA cells in media/matrix BB using CC methods for DD purpose

<b>AA</b>	<b>BB</b>	<b>CC</b>	<b>CC</b>
<b>MSC</b>	<b>Universal</b>	<b>Manual</b>	<b>Release</b>
<b>iPSC</b>	<b>media</b>	<b>Automated</b>	<b>Dose</b>
<b>Car-T</b>	<b>Cryo-</b>	<b>Impedance</b>	<b>In process</b>
<b>...</b>	<b>preservant</b>	<b>Imaging</b>	<b>Compability</b>
	<b>...</b>	<b>Flow</b>	<b>R&amp;D</b>
		<b>...</b>	<b>...</b>

- What is good enough – how to set specification using meaningful parameters

# Various approaches

- General framework vs. individualized methods
- total cell count → → various stages of cell health
- Improving the quality of “gold standard” methods → → new counting technologies

### 3. ACCURACY

The accuracy of an analytical procedure expresses the closeness of agreement between the value which is accepted either as a conventional **true value** or an **accepted reference value** and the value found.

This is sometimes termed trueness.

**Ref: VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)**

#### **Role of reference material/reference standards**

- Beads and their roles in calibration, comparability
- Cells RM as an in process control, proficiency testing
- Opportunities for new, better reference materials/what is NIST doing


# Evaluating the quality of cell counting methods in the absence of a ground truth




[ISO/WD 20391-2](#) [Under development: 20.60]

Biotechnology -- Cell Counting -- Part 2: Experimental design and statistical analysis to quantify counting method performance

## Cell Counting Results for 4 methods



- Comparability between methods
- Accuracy
- Precision
- Linearity (proportionality)
- Reproducibility





# Tools to get to “good enough”

- Strategies for better measurements
- Education materials
- Reference materials/reference standards
- Bioprocessing control (equipment, reagent, etc.)
- Competency
- Method standards

# What works well?

(ripe for standardization / best practices / SOP)

# What are ongoing efforts

- Methods and funding to keep the discussions going
- NIST certified beads consortium
- ISO Cell Counting Part 1– definitions and general considerations
- ISO Cell Counting Part 2 – method to evaluate the quality of cell counting

# What is needed?


(common understanding, methods, guidance, etc.)

- Deep dive on several case studies
- Best practices
- Spike in or other methods
- Minimum information for a specific method to provide confidence
- Inter-laboratory study / formation of consortium

# Additional Topics for NIST-FDA workshop

## ▶ FIGURE 2

An example of a generalized cell counting process that involves an automated imaging device, and where potential controls and standards for managing and minimizing sources of variability could be used.



# Working with NIST



Laboratory collaborations via joint studies, CRADA, consortium, post-doctoral opportunities, etc.



Participate in NIST workshops



Participate in standards development efforts, including inter-laboratory studies



Learn more @ [www.nist.gov](http://www.nist.gov) or search NIST Advanced Therapies

Contact: Sheng Lin-Gibson @ [slgibson@nist.gov](mailto:slgibson@nist.gov)

# Outline of a whitepaper

- Brief recap of workshop
- Key concepts
  - What works well
  - What is ongoing
    - ISO Cell Counting Part 1– definitions and general considerations
    - ISO Cell Counting Part 2 – method to evaluate the quality of cell counting
  - What is needed
    - Gaps in current guidance (communication, technical, guidance?)
    - Additional tools to improve measurement assurance



# TC276 cell characterization standard effort

based on outcomes of Jan2017 US-Japan Workshop

Cell characterization “umbrella” standard – to enable common understanding

Cell characterization measurement process standard

By attribute

Cell counting  
1 & 2

Viability ??

...

By technique

Flow Cytometry

Imaging

...

By purpose

Cell therapy products

Gene therapy products

Drug discovery

By cell type

??

??

*Cell Counting Standards are under development; all others are listed as examples*